AI Engines For more Details: Perplexity Kagi Labs You
Gastroesophageal Reflux Disease (GERD): Ranitidine is commonly prescribed to treat GERD, a condition where stomach acid flows back into the esophagus, causing heartburn and other symptoms. By reducing stomach acid production, ranitidine helps alleviate symptoms and promote healing of the esophagus.
Peptic Ulcers: Ranitidine is effective in the treatment and prevention of peptic ulcers, including gastric ulcers and duodenal ulcers. It helps to heal existing ulcers and prevent the formation of new ones by reducing stomach acid levels, which allows the lining of the stomach and duodenum to heal.
Zollinger-Ellison Syndrome: Ranitidine is used to manage Zollinger-Ellison syndrome, a rare condition characterized by excessive production of stomach acid. By inhibiting acid secretion, ranitidine helps alleviate symptoms such as abdominal pain, heartburn, and acid reflux associated with this syndrome.
Reflux Esophagitis: Ranitidine is effective in treating reflux esophagitis, a condition characterized by inflammation and irritation of the esophagus due to repeated exposure to stomach acid. By reducing acid production, ranitidine helps relieve symptoms and promote healing of the esophageal lining.
Stress Ulcer Prophylaxis: Ranitidine may be used prophylactically in critically ill patients to prevent stress ulcers, which are ulcers that develop in the stomach or duodenum due to severe illness, trauma, or surgery. By reducing gastric acid secretion, ranitidine helps reduce the risk of stress ulcer formation in these patients.
Gastritis: Ranitidine can be used to alleviate symptoms of gastritis, which is inflammation of the stomach lining. By decreasing acid production, ranitidine helps reduce irritation and inflammation of the stomach lining, thereby relieving symptoms such as abdominal pain, nausea, and indigestion.
Erosive Esophagitis: Ranitidine is effective in the treatment of erosive esophagitis, a condition characterized by erosion and ulceration of the esophageal lining due to acid reflux. By reducing acid secretion, ranitidine helps promote healing of the esophageal mucosa and alleviate symptoms such as heartburn and difficulty swallowing.
Gastric Acid Reduction: The primary mechanism of action of ranitidine is to competitively and reversibly inhibit the action of histamine on the H2 receptors of the gastric parietal cells, leading to reduced secretion of gastric acid. This results in a decrease in the acidity of gastric juice, which helps alleviate various acid-related gastrointestinal conditions.
Symptomatic Relief: Ranitidine provides symptomatic relief from conditions such as heartburn, acid indigestion, and sour stomach by reducing the production of stomach acid, thereby decreasing irritation of the esophagus and stomach lining.
Prevention of Recurrent Ulcers: In addition to treating existing ulcers, ranitidine may be used long-term to prevent the recurrence of ulcers, especially in patients who are at risk of developing them due to factors such as chronic NSAID use or H. pylori infection.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.3 | 0.3 | 0 |
| Age-Related Macular Degeneration and Glaucoma | 0.1 | 0.1 | |
| Allergies | 0.3 | 0.3 | |
| Alzheimer's disease | 1.2 | -1.2 | |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.5 | 0.5 | |
| Ankylosing spondylitis | 0.3 | -0.3 | |
| Anorexia Nervosa | 0.5 | -0.5 | |
| Asthma | 0.7 | 0.1 | 6 |
| Atherosclerosis | 0.1 | -0.1 | |
| Atrial fibrillation | 0.4 | 0.4 | |
| Autism | 1 | 1.3 | -0.3 |
| Bipolar Disorder | 0.5 | -0.5 | |
| Brain Trauma | 0.1 | -0.1 | |
| Carcinoma | 0.3 | 0.3 | |
| Celiac Disease | 0.1 | 0.3 | -2 |
| Cerebral Palsy | 0.1 | -0.1 | |
| Chronic Fatigue Syndrome | 1.2 | 0.1 | 11 |
| Chronic Kidney Disease | 0.4 | 0.7 | -0.75 |
| Chronic Lyme | 0.1 | -0.1 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.4 | -0.4 | |
| Coagulation / Micro clot triggering bacteria | 0.1 | -0.1 | |
| Colorectal Cancer | 0.1 | 0.1 | 0 |
| Constipation | 0.3 | 0.1 | 2 |
| Coronary artery disease | 0.1 | 0.1 | |
| COVID-19 | 1 | 1.5 | -0.5 |
| Crohn's Disease | 0.5 | 1.2 | -1.4 |
| cystic fibrosis | 0.1 | -0.1 | |
| deep vein thrombosis | 0.1 | -0.1 | |
| Depression | 1.8 | 0.5 | 2.6 |
| Endometriosis | 0.3 | -0.3 | |
| Fibromyalgia | 0.1 | 0.1 | |
| Functional constipation / chronic idiopathic constipation | 0.3 | 0.2 | 0.5 |
| gallstone disease (gsd) | 0.1 | -0.1 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.1 | 0.1 | |
| Graves' disease | 0.1 | -0.1 | |
| Hashimoto's thyroiditis | 0.2 | 0.2 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.6 | 0.2 | 2 |
| hypertension (High Blood Pressure | 0.4 | -0.4 | |
| Hypothyroidism | 0.3 | -0.3 | |
| IgA nephropathy (IgAN) | 0.5 | -0.5 | |
| Inflammatory Bowel Disease | 0.3 | 0.8 | -1.67 |
| Insomnia | 0.4 | -0.4 | |
| Irritable Bowel Syndrome | 0.1 | 0.5 | -4 |
| Liver Cirrhosis | 0.1 | 0.1 | 0 |
| Long COVID | 0.8 | 1 | -0.25 |
| Low bone mineral density | 0.4 | -0.4 | |
| ME/CFS without IBS | 1.2 | 1.2 | |
| Metabolic Syndrome | 0.5 | 0.5 | 0 |
| Mood Disorders | 1.8 | 0.9 | 1 |
| Multiple Sclerosis | 1 | 0.9 | 0.11 |
| Multiple system atrophy (MSA) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.5 | -0.5 | |
| Obesity | 0.5 | 0.5 | |
| obsessive-compulsive disorder | 0.3 | 0.2 | 0.5 |
| Osteoporosis | 0.3 | 0.3 | |
| Parkinson's Disease | 0.3 | 0.5 | -0.67 |
| Polycystic ovary syndrome | 0.1 | 0.1 | 0 |
| Psoriasis | 0.1 | -0.1 | |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.7 | 0.1 | 6 |
| Rosacea | 0.1 | 0.1 | 0 |
| Schizophrenia | 0.6 | 0.1 | 5 |
| scoliosis | 0.5 | -0.5 | |
| Sjögren syndrome | 0.1 | -0.1 | |
| Sleep Apnea | 0.5 | -0.5 | |
| Stress / posttraumatic stress disorder | 0.1 | 0.8 | -7 |
| Systemic Lupus Erythematosus | 0.3 | 0.4 | -0.33 |
| Tic Disorder | 0.1 | 0.1 | |
| Type 1 Diabetes | 0.1 | 0.5 | -4 |
| Type 2 Diabetes | 0.5 | 0.2 | 1.5 |
| Ulcerative colitis | 0.2 | -0.2 | |
| Unhealthy Ageing | 0.5 | 0.4 | 0.25 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.